Major Alzheimer’s Association grant to enable researchers to test a drug that could slow the progression of Alzheimer’s disease.
Drug Studied at Butler Hospital’s Memory and Aging Program May Become First New Treatment for Alzheimer’s in 16 Years
Aducanumab maker Biogen seeking FDA review in early 2020; if approved, it will become the first drug to remove amyloid protein from the brain and slow the progression of Alzheimer’s disease (AD).
Dr. Hwamee Oh Named Director of Imaging Research for The Memory and Aging Program at Butler Hospital
Dr. Oh will research the use of imaging to detect Alzheimer’s before symptoms appear, offering patients a chance at early intervention.
Memory and Aging Program Director Dr. Stephen Salloway on the growing health crisis and how all Rhode Islanders ages 40 to 85 can help.
A look inside the Memory and Aging Program at Butler Hospital and how Southern New Englanders are contributing to the mounting battle against Alzheimer’s.
Clinical Trials Aimed at Preventing Alzheimer’s to Begin at Butler Hospital’s Memory and Aging Program
The Memory and Aging Program at Butler Hospital will launch trials of two new treatments aimed at preventing Alzheimer’s in early 2020.
Study: Amyloid Plaques in Brain Linked to Greater Growth of Tau “Tangles,” Development of Alzheimer’s
The study provides new insight into how plaques lead to cognitive decline and supports use of PET imaging to predict and diagnose dementia.
Stephen Salloway, MD, Global Leader in Alzheimer’s Research, Inducted Into Rhode Island Heritage Hall of Fame
Dr. Salloway and his team at the Memory and Aging Program at Butler Hospital are global leaders in the fight against Alzheimer’s.
The results of a landmark trial conducted in part at the Memory and Aging Program at Butler Hospital show that amyloid PET brain scan imaging significantly improves both the accuracy of diagnosis and the subsequent medical management of patients with mild cognitive impairment and dementia.
Memory and Aging Program Director Dr. Stephen Salloway, a study co-author, calls the findings a “game changer” in Alzheimer’s research.